company background image
ACTI

Active Biotech OM:ACTI Stock Report

Last Price

kr0.93

Market Cap

kr256.4m

7D

-12.3%

1Y

-33.7%

Updated

28 Sep, 2022

Data

Company Financials
ACTI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ACTI Stock Overview

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden.

Active Biotech AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Active Biotech
Historical stock prices
Current Share Pricekr0.93
52 Week Highkr1.52
52 Week Lowkr0.88
Beta0.90
1 Month Change-8.47%
3 Month Change-24.02%
1 Year Change-33.67%
3 Year Change-65.81%
5 Year Change-84.24%
Change since IPO-97.15%

Recent News & Updates

May 07
Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

ACTISE BiotechsSE Market
7D-12.3%-6.4%-3.3%
1Y-33.7%-40.0%-28.2%

Return vs Industry: ACTI exceeded the Swedish Biotechs industry which returned -40% over the past year.

Return vs Market: ACTI underperformed the Swedish Market which returned -28.2% over the past year.

Price Volatility

Is ACTI's price volatile compared to industry and market?
ACTI volatility
ACTI Average Weekly Movement8.6%
Biotechs Industry Average Movement8.0%
Market Average Movement6.9%
10% most volatile stocks in SE Market11.7%
10% least volatile stocks in SE Market4.3%

Stable Share Price: ACTI is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ACTI's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19839Helen Tuvessonhttps://www.activebiotech.com

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd.

Active Biotech AB (publ) Fundamentals Summary

How do Active Biotech's earnings and revenue compare to its market cap?
ACTI fundamental statistics
Market Capkr256.41m
Earnings (TTM)-kr57.42m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACTI income statement (TTM)
Revenuekr0
Cost of Revenuekr0
Gross Profitkr0
Other Expenseskr57.43m
Earnings-kr57.42m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 03, 2022

Earnings per share (EPS)-0.22
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ACTI perform over the long term?

See historical performance and comparison